Similar articles

• [Efficacy of bicalutamide in adjuvant treatment of prostatic carcinoma after primary therapy with curative aim. The viewpoint of the surgeon].

  Rigatti P, Scattoni V. Rigatti P, et al. Recenti Prog Med. 2002 Mar;93(3):183-5. Recenti Prog Med. 2002. PMID: 11942171 Italian. No abstract available.
• Randomized controlled trial to evaluate radiotherapy +/- endocrine therapy versus endocrine therapy alone for PSA failure after radical prostatectomy: Japan Clinical Oncology Group Study JCOG 0401.

  Yokomizo A, Kawamoto H, Nihei K, Ishizuka N, Kakehi Y, Tobisu K, Naito S; Japan Clinical Oncology Group. Yokomizo A, et al. Jpn J Clin Oncol. 2005 Jan;35(1):34-6. doi: 10.1093/jjco/hyi007. Jpn J Clin Oncol. 2005. PMID: 15681602 Clinical Trial.
• [Preliminary results of casodex use in patients with hormone-resistant cancer of the prostate].

  Matveev BP, Bukharkin BV. Matveev BP, et al. Urologiia. 2001 Nov-Dec;(6):20-1. Urologiia. 2001. PMID: 11785074 Clinical Trial. Russian. No abstract available.
• [Endocrine therapy for prostate cancer in the future].

  Usami M. Usami M. Gan To Kagaku Ryoho. 1998 May;25(6):817-22. Gan To Kagaku Ryoho. 1998. PMID: 9617319 Review. Japanese.
• [Total androgen blockade].

  Namiki M, Mizokami A. Namiki M, et al. Nihon Rinsho. 2002 Dec;60 Suppl 11:193-8. Nihon Rinsho. 2002. PMID: 12599570 Review. Japanese. No abstract available.